Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celebrex TV Ads Modified After FDA Says Pharmacia Overstated Efficacy

Executive Summary

Pharmacia modified a Celebrex direct-to-consumer advertising campaign after FDA found that television spots for the product exaggerated the efficacy of the arthritis drug.

You may also be interested in...



FDA Cites Abbott’s Humira Psoriasis Ad: Patient Does Not Exhibit Severe Disease

Warning letter for Humira ad reprises agency interest in clear identification of appropriate patients.

Celebrex, Bextra Ads Draw Fire From FDA; Reminder Of “Reminder” Ad Rules

An FDA "untitled" letter to Pfizer on Celebrex and Bextra is the agency's second recent objection to the company's interpretation of the boundaries of "reminder" ads

Celebrex, Bextra Ads Draw Fire From FDA; Reminder Of “Reminder” Ad Rules

An FDA "untitled" letter to Pfizer on Celebrex and Bextra is the agency's second recent objection to the company's interpretation of the boundaries of "reminder" ads

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel